by Elena Kondakova | Igor Yusipov | Nadezhda Lobanova | Mikhail Ivanchenko | Maria Vedunova |
Institute of Biology and Biomedicine, Lobachevsky University, Nizhny Novgorod, Russia | Institute of
Information Technologies, Mathematics and Mechanics, Lobachevsky University, Nizhny Novgorod,
Russia | Institute of Biology and Biomedicine, Lobachevsky University, Nizhny Novgorod, Russia |
Institute of Information Technologies, Mathematics and Mechanics, Lobachevsky University, Nizhny
Novgorod, Russia | Institute of Biology and Biomedicine, Lobachevsky University, Nizhny Novgorod,
Russia
Accelerated aging is a process associated with the accumulation of harmful changes in the
body and an increased risk of disease and death. Despite advances in the treatment of
chronic kidney disease and optimization of the hemodialysis process in end-stage renal
disease (ESRD), morbidity and mortality in this group of people remain constantly high.
Identification of markers of accelerated aging and mortality risk will allow finding possible
interventions to increase the duration and improve the quality of life of patients. The study
participants were men and women aged 24 to 89 years. Of the 420 participants in the study,
two groups were selected (patients with ESRD and controls) with the maximum match in
age and gender. We demonstrated that ESRD is associated with the significant acceleration
of biological age compared with the control group. There was a statistically significant
increase in the content of all biomarkers (FGF21 GDF15, CXCL9) presented in the ESRD
group compared to the controls. We analyzed patients in terms of one-year survival and
dividing the group of patients according to the disease outcome showed a significant
increase in the FGF21 content in the ESRD group with unfavorable one-year survival
prognoses. We developed an estimator of biological age based on the blood concentration of
three biomarkers: Age-Estimation Clock. When analyzing the one-year survival prognosis, a
significant increase in Age-Estimation Clock was found in the group of deceased patients.
These findings, together with the evidence on the high prognostic value of FGF21 as a risk
of mortality factor in patients with ESRD, opens up the possibility of further improvement of
the model’s predictive value and the risk group identification.